Hepatitis B Functional-Cure Treatment Reaches FDA Approval

GSK’s Hibsago (bepirovirsen) received FDA approval after Phase 3 results reported functional cure in 19% versus none on placebo, rising to 26% in participants with lower baseline surface antigen. The benefit is clinically notable but limited to a selected group; boxed warnings, durability, and practical eligibility require follow-up.